A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Active:	Yes
Cancer Type:	Breast Cancer	NCT ID:	NCT04961996
Trial Phases:	Phase III	Protocol IDs:	GO42784 (primary) NCI-2021-09253 2021-000129-28
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT04961996

Summary

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the
efficacy and safety of adjuvant giredestrant compared with endocrine therapy of
physician's choice in participants with medium- and high-risk Stage I-III histologically
confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2
(HER2)-negative early breast cancer.

In addition, an open-label exploratory substudy will explore the safety and efficacy of
giredestrant in combination with abemaciclib in a subset of the primary study population.

Treatment Sites in Georgia

Northwest Georgia Oncology Centers - Cobb Hospital (Hiram)
144 Bill Carruth Parkway
Suite 3100
Hiram, GA 30141
770-281-5131
www.ngoc.com

Doctors:

Kathleen A. Long MD

Aron E. Kefela MD

Northwest Georgia Oncology Centers - Tanner Medical Center Villa Rica
157 Clinic Avenue
Suite 101 and Suite 102
Carrollton, GA 30117
770-281-5101
www.ngoc.com

Doctors:

Bradley J.G. Larson MD

Randall E. Pierce MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.